Portalac, syrup, 250ml

Composition

>

of 100 ml of syrup contains:

Active ingredient:  

lactulose concentrate 66.7 g;

Auxiliary substances:

purified water.

Pharmacological action

Portalac is a hypo-azotemic laxative that stimulates intestinal motility.

Pharmacodynamics

It has a hyperosmotic, laxative effect, stimulates intestinal motility, improves the absorption of phosphates and Ca2+ salts, and promotes the elimination of ammonium ions.

Under the influence of lactulose, reproduction occurs Lactobacillus acidophilus, Lactobacillus bifidus in the intestine, which in turn leads to a decrease in pH in the lumen of the large intestine and activation of its peristalsis. Along with this, the volume increases and the stool softens. The drug has a laxative effect, without directly affecting the mucous membrane and smooth muscles of the large intestine.

Under the influence of lactulose, the formation of nitrogen-containing toxic substances in the proximal colon and their absorption into the systemic circulation decreases.

The concentration of ammonium ions in the blood decreases by 25-50%; reduces the severity of hepatic encephalopathy, improves mental state and normalizes EEG.

The drug has the ability to inhibit the growth of salmonella in the large intestine.

The effect of the drug occurs 24-48 hours after oral use, as the drug passes through

the gastrointestinal tract.

Lactulose is practically not absorbed from the gastrointestinal tract (no more than 3% of the dose is absorbed), does not reduce the absorption of vitamins, and is not addictive.

Indications

• Constipation of various etiologies (including chronic);
• the need to soften chair for medical purposes (if hemorrhoids need surgery on the colon and/or the anus, pain syndrome after removal of hemorrhoids, postoperative period);
• intestinal dysbiosis;
• hepatic encephalopathy;
• hepatic precoma and coma (treatment and prevention);
• the hyperammonemia;
• enteritis caused by Salmonella, Shigella, salmonellosis;
• syndrome of putrefactive dyspepsia (in children of early age as a result of acute food poisoning).

Use during pregnancy and lactation

Lactulose can be safely used in pregnant and lactating mothers.

Contraindications

• Hypersensitivity to lactulose or other components of the drug;
• galactosemia;
• intestinal obstruction;
• rectal bleeding (which is not caused by hemorrhoids);
• colo – or ileostoma;
• suspected appendicitis.

Caution should be exercised when prescribing the drug to patients with gastrocardiac syndrome: treatment begins with low doses and increases them gradually to avoid flatulence.

Due to the presence of small amounts of sugars in the preparation (15 ml of syrup contains up to 1.7 g of galactose and up to 1 g of lactose), caution should be exercised when prescribing the drug to patients with diabetes mellitus and lactose intolerance.

Side effects

Side effects are usually mild and reversible and are the result of exceeding the dose.

Cramps, discomfort or abdominal pain, as well as diarrhea can be eliminated by reducing the dose. Flatulence that appears at the beginning of treatment, as a rule, passes in 1-2 days.

Skin reactions (rash) have been reported.

With prolonged therapy and the use of high doses of lactulose in the treatment of hepatic encephalopathy, a violation of the water-electrolyte balance may develop, and as a result, convulsions, nausea, headache, dizziness, arrhythmia, myalgia, fatigue, weakness.

Interaction

When using therapeutic doses of lactulose, clinically significant interactions with other drugs were not observed. However, it is not recommended to take Portalac® within 2 hours after taking another drug.

When taken concomitantly, lactulose may interfere with the action of drugs that create an unfavorable environment in the large intestine (for example, drugs containing mesalazine).

Antibiotics (neomycin) and antacids reduce the effect.

How to take, course of use and dosage

Portalak is taken orally, in the morning during or after meals, once or divided into 2 doses, washed down with water or other liquid. The dose of Portalac is selected individually. The initial dose (3 days) is:

Children under 1 year of age: 5 ml (1 teaspoon);

Children from 1 year to 6 years of 5-10 ml (1-2 teaspoons);

Children from 6 to 14 years,15 ml (1 tbsp. spoon).

Adults take 15-45 ml.

Overdose

Symptoms:  taking too high doses of the drug can cause diarrhea and a violation of the water-electrolyte balance. Treatment:  discontinuation of the drug.

Special instructions

If constipation persists within a few days of taking the drug, or if constipation resumes after stopping taking the drug, you should consult your doctor.

Due to the presence of small amounts of sugars in the preparation (15 ml of syrup contains up to 1.7 g of galactose and up to 1 g of lactose), caution should be exercised when prescribing the drug to patients with diabetes mellitus and lactose intolerance.

Caution should be exercised when prescribing the drug to patients with gastrocardiac syndrome: treatment begins with low doses and increases them gradually to avoid flatulence.

In the treatment of hepatic encephalopathy, especially in the initial phase of therapy, other laxatives should not be used, since increased bowel emptying may lead to an erroneous conclusion about achieving an adequate dose for the treatment of encephalopathy.

Influence on the ability to drive a car or perform work that requires an increased rate of physical and mental reactions. At the recommended doses, the drug does not affect the ability to drive vehicles and mechanisms.

Form of production

Syrup

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Lactulose

Dosage form

solution for oral use

Description

Pregnant women as prescribed by a doctor, For children, For adults, Nursing mothers as prescribed by a doctor

Indications

Salmonellosis, Hemorrhoids, Liver Damage, Constipation, Enteritis, Dysbiosis